Locked nucleic acid-enhanced detection of 1100delC*CHEK2 germ-line mutation in Spanish patients with hematologic malignancies

Clinical Chemistry

Volumn 50, Issue 11, 2004, Pages 2201-2204

  Collado, María ^a   Landt, Olfert ^b   Barragán, Eva ^a   Lass, Ulrich ^b   Cervera, José ^a   Sanz, Miguel A ^a   Boluferl, Pascual ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b TIB MOLBIOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE 2; NUCLEIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CELL CYCLE G2 PHASE; CHROMOSOME 22Q; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; EWING SARCOMA; FAMILIAL CANCER; FEMALE; FOLLICULAR LYMPHOMA; GERM LINE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; KARYOTYPING; LEUKEMIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MUTATION; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PROSTATE CANCER; REFRACTORY ANEMIA WITH EXCESS BLASTS; SIGMOID CARCINOMA; SOMATIC MUTATION; SPAIN; TONGUE CARCINOMA; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; WALDENSTROEM MACROGLOBULINEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GERM-LINE MUTATION; HUMANS; INFANT; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROTEIN-SERINE-THREONINE KINASES; SPAIN;

SIGMOIDEA;

EID: 7044222405     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.038331     Document Type: Article

References (14)

1. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2* 11OOdelC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
2. Online Mendelian Inheritance in Man (OMIM). Checkpoint kinase 2 (604373). http://www.ncbi.nlm.nih.gov/Omin/ (accessed June 21, 2004).
3. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998;282:1893-7.
4. Falck J, Mailand N, Syljuasen RG, Barket J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-7.
5. Wu X, Webster SR, Chen J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001;276:2971-4.
6. Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002;71:432-8.
7. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003;72:270-80.
8. Hangaishi A, Ogawa S, Qiao Y, Wang L, Hosoya N, Yuji K, et al. Mutations of Chk2 in primary hematopoietic neoplasms [Correspondence]. Blood 2002;99:3075-7.
9. Aktas D, Arno MJ, Rassool F, Mufti GJ. Analysis of CHK2 in patients with myelodysplastic syndromes. Leukemia Res 2002;26:985-7.
10. Tort F, Hernández S, Beá S, Martínez A, Esteller M, Herman JG, et al. CHK2 decreased protein expression and infrequent genetic alterations mainly occur in aggressive type of non-Hodgkin's lymphomas. Blood 2002;100:4602-8.
11. Sodha N, Houlston RS, Williams R, Yuille MA, Mangion J, Eeles RA. A robust method for detecting CHEK2/RAD53 mutations in genomic DNA. Hum Mutat 2002;19:173-7.
12. Jacobsen N, Bentzen J, Meldgaard M, Jakobsen MH, Fenger M, Kauppinen S, et al. LNA-enhanced detection of single nucleotide polymorphisms in the apolipoprotein E. Nucleic Acids Res 2002;30:e100.
13. Osorio A, Rodríguez-López R, Díez O, de la Hoya M, Martinez JI, Vega A, et al. The breast cancer low-penetrance allele 1100delC in the Chek2 gene is not present in Spanish familial breast cancer population. Int J Cancer 2004;108:54-6.
14. Kenneth O, Heather P, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P, et al. Frequency of CHEK*110C in New York breast cancer cases and controls. BMC Med Genet 2003;4:1 (http//www.biomedcentral.com/1471-2350/4/1).